Clinical Trial Design Challenges in Mood Disorders

Clinical Trial Design Challenges in Mood Disorders
Author: Mauricio Tohen,Charles Bowden,Andrew A. Nierenberg,John Geddes
Publsiher: Academic Press
Total Pages: 192
Release: 2015-01-24
ISBN 10: 0124051766
ISBN 13: 9780124051768
Language: EN, FR, DE, ES & NL

Clinical Trial Design Challenges in Mood Disorders Book Review:

Poor clinical trial designs result in failed studies wasting research funds and limiting the advancement of cures for disorders. Clinical Trial Design Challenges in Mood Disorders outlines classic problems researchers face in designing clinical trials and discusses how best to address them for the most definitive and generalizable results. Traditional trial designs are included as well as novel analytic techniques. The book examines information on high placebo response, the generalizability of studies conducted in the developing world, the duration of maintenance studies, and the application of findings into clinical practice. With representation from contributors throughout the world and from academia, industry, regulatory agencies, and advocacy groups, this book will contribute toward improved clinical trial design and valid, precise, and reliable answers about what works better and faster for patients. Summarizes common trial design problems and their solutions Encompasses funding, subject selection, regulatory issues and more Identifies best practices for definitive and generalizable results Includes traditional trial designs and novel analytic techniques Represents academia, industry, regulatory agencies, and advocacy groups

Neuroscience Trials of the Future

Neuroscience Trials of the Future
Author: National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 110
Release: 2016-12-07
ISBN 10: 0309442559
ISBN 13: 9780309442558
Language: EN, FR, DE, ES & NL

Neuroscience Trials of the Future Book Review:

On March 3-4, 2016, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders. Participants in the workshop represented a range of diverse perspectives, including individuals not normally associated with traditional clinical trials. The purpose of this workshop was to generate discussion about not only what is feasible now, but what may be possible with the implementation of cutting-edge technologies in the future.

Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 118
Release: 2014-02-06
ISBN 10: 0309292492
ISBN 13: 9780309292498
Language: EN, FR, DE, ES & NL

Improving and Accelerating Therapeutic Development for Nervous System Disorders Book Review:

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

The Medical Basis of Psychiatry

The Medical Basis of Psychiatry
Author: S. Hossein Fatemi,Paula J. Clayton
Publsiher: Springer
Total Pages: 1064
Release: 2016-03-17
ISBN 10: 1493925288
ISBN 13: 9781493925285
Language: EN, FR, DE, ES & NL

The Medical Basis of Psychiatry Book Review:

Four years have passed since the last edition (3rd) of this book was published. In the intervening years, several reviews of this book have provided highly encouraging remarks about the value of this book in transmitting information on classification and treatment of psychiatric disorders to the audience. We are proposing to revise all chapters with an eye on accuracy and ease of use, and this is an especially timely endeavor with the upcoming publication of the Diagnostic and Statistical Manual V. All the appropriate new information on biology, etiology, diagnosis and treatment of psychiatric disorders will be added to the current proposed edition. It is our goal to recruit the same authors (if possible) who contributed to the previous edition. While all chapters will be updated (see TOC), those marked by asterisks will be the most likely to undergo more revision. Psychiatry has emerged as a burgeoning scientific field with major advances in etiology and treatment of several disorders. Just as there was excitement in the anatomic advances that took place a hundred years ago when Emil Kraepelin and his collaborators took on the enormous task of classification of psychiatric disorders based on rational scientific thinking, new advances in genetics, biochemistry, neuroanatomy and pharmacotherapy of mental disorders have brought us even closer to a better understanding of complex disorders like schizophrenia, bipolar disorder, depression and even autism. The major goal of the previous edition of this classic book was to update the busy clinician, psychiatric resident and medical student with the most up-to-date information on etiology, diagnosis and treatment of psychiatric disorders. This goal remains the focus of the fourth edition of this book. In this updated and expanded edition, the reader will be provided with the most contemporary information and literature supported by a close survey of the field. This new edition of this classic title, with its focus on biologic and medical aspects of psychiatry, will continue to be of significant help to all interested in the scientific practice of psychiatry.

Small Clinical Trials

Small Clinical Trials
Author: Institute of Medicine,Board on Health Sciences Policy,Committee on Strategies for Small-Number-Participant Clinical Research Trials
Publsiher: National Academies Press
Total Pages: 222
Release: 2001-01-01
ISBN 10: 9780309171144
ISBN 13: 0309171148
Language: EN, FR, DE, ES & NL

Small Clinical Trials Book Review:

Clinical trials are used to elucidate the most appropriate preventive, diagnostic, or treatment options for individuals with a given medical condition. Perhaps the most essential feature of a clinical trial is that it aims to use results based on a limited sample of research participants to see if the intervention is safe and effective or if it is comparable to a comparison treatment. Sample size is a crucial component of any clinical trial. A trial with a small number of research participants is more prone to variability and carries a considerable risk of failing to demonstrate the effectiveness of a given intervention when one really is present. This may occur in phase I (safety and pharmacologic profiles), II (pilot efficacy evaluation), and III (extensive assessment of safety and efficacy) trials. Although phase I and II studies may have smaller sample sizes, they usually have adequate statistical power, which is the committee's definition of a "large" trial. Sometimes a trial with eight participants may have adequate statistical power, statistical power being the probability of rejecting the null hypothesis when the hypothesis is false. Small Clinical Trials assesses the current methodologies and the appropriate situations for the conduct of clinical trials with small sample sizes. This report assesses the published literature on various strategies such as (1) meta-analysis to combine disparate information from several studies including Bayesian techniques as in the confidence profile method and (2) other alternatives such as assessing therapeutic results in a single treated population (e.g., astronauts) by sequentially measuring whether the intervention is falling above or below a preestablished probability outcome range and meeting predesigned specifications as opposed to incremental improvement.

Transforming Clinical Research in the United States

Transforming Clinical Research in the United States
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
Publsiher: National Academies Press
Total Pages: 150
Release: 2010-10-22
ISBN 10: 9780309163354
ISBN 13: 0309163358
Language: EN, FR, DE, ES & NL

Transforming Clinical Research in the United States Book Review:

An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise.

Personalized Psychiatry

Personalized Psychiatry
Author: Bernhard Baune
Publsiher: Academic Press
Total Pages: 604
Release: 2019-10-16
ISBN 10: 0128131772
ISBN 13: 9780128131770
Language: EN, FR, DE, ES & NL

Personalized Psychiatry Book Review:

Personalized Psychiatry presents the first book to explore this novel field of biological psychiatry that covers both basic science research and its translational applications. The book conceptualizes personalized psychiatry and provides state-of-the-art knowledge on biological and neuroscience methodologies, all while integrating clinical phenomenology relevant to personalized psychiatry and discussing important principles and potential models. It is essential reading for advanced students and neuroscience and psychiatry researchers who are investigating the prevention and treatment of mental disorders. Combines neurobiology with basic science methodologies in genomics, epigenomics and transcriptomics Demonstrates how the statistical modeling of interacting biological and clinical information could transform the future of psychiatry Addresses fundamental questions and requirements for personalized psychiatry from a basic research and translational perspective

Alzheimer s Disease

Alzheimer s Disease
Author: Jolanta Dorszewska,Wojciech Kozubski
Publsiher: BoD – Books on Demand
Total Pages: 162
Release: 2018-07-18
ISBN 10: 178923462X
ISBN 13: 9781789234626
Language: EN, FR, DE, ES & NL

Alzheimer s Disease Book Review:

Alzheimer's disease was discovered over 100 years ago and still belongs to incurable neurological diseases; its pharmacotherapy is considered to be ineffective. This book presents contemporary views on the genetic, biochemical, and immunological determinants of this disease. This book also concerns the issue of Alzheimer's disease prevention through lifestyle and physical activity. Moreover, it describes the therapies used in Alzheimer's disease to slow the progression of the disease and delay its onset. Subsequently, the authors discuss experimental and clinical trials used now and in the near future. We hope that this book will help the readers to understand the complex mechanism leading to the development of Alzheimer's disease and indicate effective ways to prevent this disorder.

Complex Disorders in Pediatric Psychiatry

Complex Disorders in Pediatric Psychiatry
Author: David I Driver,Shari Thomas
Publsiher: Elsevier Health Sciences
Total Pages: 250
Release: 2018-03-27
ISBN 10: 0323511724
ISBN 13: 9780323511728
Language: EN, FR, DE, ES & NL

Complex Disorders in Pediatric Psychiatry Book Review:

Get a quick, expert overview of complex childhood psychiatric disorders from Drs. David I. Driver and Shari Thomas of Healthy Foundations Group. This practical resource presents a summary of today’s current knowledge and best approaches to topics from gender dysphoria to childhood onset schizophrenia and other complex psychiatric disorders. Comprehensive guide for any professional working with children. Consolidates today’s evidence-based information on complex childhood psychiatric disorders into one convenient resource. Provides must-know information on evaluation and management. Covers a range of psychiatric disorders of children including drug-induced mania and psychosis, concussions, ADHD, technology addiction, sleep disorders, and eating disorders.

The Science and Practice of Lithium Therapy

The Science and Practice of Lithium Therapy
Author: Gin S. Malhi,Marc Masson,Frank Bellivier
Publsiher: Springer
Total Pages: 342
Release: 2016-11-24
ISBN 10: 3319459236
ISBN 13: 9783319459233
Language: EN, FR, DE, ES & NL

The Science and Practice of Lithium Therapy Book Review:

This book provides a clear and comprehensive guide to the clinical prescription of lithium that draws upon evidence-based knowledge of its mechanisms of action. The book is divided into two parts, on the science of lithium and the practice of lithium therapy. The former covers aspects such as the properties of the lithium ion, pharmacokinetics and pharmacodynamics, impact on neurotransmission, and gene expression modulation. The section on practice includes discussion of variability in response to lithium, use of lithium in the treatment of bipolar disorders, its value in suicide prevention, administration during pregnancy and in the pediatric age group, and side effects. Lithium is arguably the only true mood stabilizer, and its multifaceted effects across many clinical domains have given rise to a resurgence of interest in recent years, fuelled by both researchers and clinicians. Nevertheless, its use remains constrained by exaggerated concerns about potential side-effects. In reality, lithium is a simple molecule that is relatively straightforward to administer and monitor and has potentially profound benefits at a fraction of the cost of contemporary agents. This book dispels the many myths and concerns that surround its use and will be of interest for clinicians and researchers worldwide, and those that are recipients of lithium therapy.

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults Third Edition

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults  Third Edition
Author: American Psychiatric Association
Publsiher: American Psychiatric Pub
Total Pages: 170
Release: 2015-07-29
ISBN 10: 0890424659
ISBN 13: 9780890424650
Language: EN, FR, DE, ES & NL

The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults Third Edition Book Review:

Since the publication of the Institute of Medicine (IOM) report Clinical Practice Guidelines We Can Trust in 2011, there has been an increasing emphasis on assuring that clinical practice guidelines are trustworthy, developed in a transparent fashion, and based on a systematic review of the available research evidence. To align with the IOM recommendations and to meet the new requirements for inclusion of a guideline in the National Guidelines Clearinghouse of the Agency for Healthcare Research and Quality (AHRQ), American Psychiatric Association (APA) has adopted a new process for practice guideline development. Under this new process APA's practice guidelines also seek to provide better clinical utility and usability. Rather than a broad overview of treatment for a disorder, new practice guidelines focus on a set of discrete clinical questions of relevance to an overarching subject area. A systematic review of evidence is conducted to address these clinical questions and involves a detailed assessment of individual studies. The quality of the overall body of evidence is also rated and is summarized in the practice guideline. With the new process, recommendations are determined by weighing potential benefits and harms of an intervention in a specific clinical context. Clear, concise, and actionable recommendation statements help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. The new practice guideline format is also designed to be more user friendly by dividing information into modules on specific clinical questions. Each module has a consistent organization, which will assist users in finding clinically useful and relevant information quickly and easily. This new edition of the practice guidelines on psychiatric evaluation for adults is the first set of the APA's guidelines developed under the new guideline development process. These guidelines address the following nine topics, in the context of an initial psychiatric evaluation: review of psychiatric symptoms, trauma history, and treatment history; substance use assessment; assessment of suicide risk; assessment for risk of aggressive behaviors; assessment of cultural factors; assessment of medical health; quantitative assessment; involvement of the patient in treatment decision making; and documentation of the psychiatric evaluation. Each guideline recommends or suggests topics to include during an initial psychiatric evaluation. Findings from an expert opinion survey have also been taken into consideration in making recommendations or suggestions. In addition to reviewing the available evidence on psychiatry evaluation, each guideline also provides guidance to clinicians on implementing these recommendations to enhance patient care.

Wiley Encyclopedia of Clinical Trials

Wiley Encyclopedia of Clinical Trials
Author: Lisa Marie Sullivan,Joseph Massaro
Publsiher: Wiley-Interscience
Total Pages: 1374
Release: 2008
ISBN 10:
ISBN 13: UCLA:L0099757635
Language: EN, FR, DE, ES & NL

Wiley Encyclopedia of Clinical Trials Book Review:

Here you'll find more than 500 entries from the world's leading experts in the field on the basic concepts, methodologies, and applications in clinical trials. The range of topics includes: basic statistical concepts, design and analysis of clinical trials, ethics, regulatory issues, and methodologies for clinical data management and analysis

GABA and Mood Disorders

GABA and Mood Disorders
Author: Giuseppe Bartholini,K. G. Lloyd,Paolo Lucio Morselli
Publsiher: Unknown
Total Pages: 222
Release: 1986
ISBN 10:
ISBN 13: UOM:39015010649294
Language: EN, FR, DE, ES & NL

GABA and Mood Disorders Book Review:

The Handbook of Neuropsychiatric Biomarkers Endophenotypes and Genes

The Handbook of Neuropsychiatric Biomarkers  Endophenotypes and Genes
Author: Michael Ritsner
Publsiher: Springer Science & Business Media
Total Pages: 273
Release: 2009-04-21
ISBN 10: 1402094647
ISBN 13: 9781402094644
Language: EN, FR, DE, ES & NL

The Handbook of Neuropsychiatric Biomarkers Endophenotypes and Genes Book Review:

Neuropsychiatric disorders such as schizophrenia, mood disorders, Alzheimer’s disease, epilepsy, alcoholism, substance abuse and others are some of the most debilitating illnesses worldwide characterizing by the complexity of the causes, and lacking the laboratory tests that may promote diagnostic and prognostic procedures. Recent advances in neuroscience, genomic, genetic, proteomic and metabolomic knowledge and technologies have opened the way to searching biomarkers and endophenotypes, which may offer powerful and exciting opportunity to understand the etiology and the underlying pathophysiological mechanisms of neuropsychiatric disorders. The challenge now is to translate these advances into meaningful diagnostic and therapeutic advances. This book offers a broad synthesis of the current knowledge about diverse topics of the biomarker and endophenotype strategies in neuropsychiatry. The book is organized into four interconnected volumes: “Neuropsychological Endophenotypes and Biomarkers” (with overview of methodological issues of the biomarker and endophenotype approaches in neuropsychiatry and some technological advances), “Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers”, “Metabolic and Peripheral Biomarkers” and “Molecular Genetic and Genomic Markers”. The contributors are internationally and nationally recognized researchers and experts from 16 countries. This four-volume handbook is intended for a broad spectrum of readers including neuroscientists, psychiatrists, neurologists, endocrinologists, pharmacologists, clinical psychologists, general practitioners, geriatricians, health care providers in the field of neurology and mental health interested in trends that have crystallized in the last decade, and trends that can be expected to further evolve in the coming years. It is hoped that this book will also be a useful resource for the teaching of psychiatry, neurology, psychology and mental health.

Cognitive Dysfunction in Bipolar Disorder

Cognitive Dysfunction in Bipolar Disorder
Author: Joseph F. Goldberg,Katherine Burdick
Publsiher: American Psychiatric Pub
Total Pages: 316
Release: 2009-02-20
ISBN 10: 1585628875
ISBN 13: 9781585628872
Language: EN, FR, DE, ES & NL

Cognitive Dysfunction in Bipolar Disorder Book Review:

A growing body of clinical and experimental evidence shows that neurocognitive dysfunction is a fundamental -- yet frequently ignored or misidentified -- component of bipolar disorder. The first comprehensive book of its kind, Cognitive Dysfunction in Bipolar Disorder: A Guide for Clinicians compiles the latest data in neuropsychology, neuroimaging, neurogenetics, and functional outcomes research to enable clinicians to more effectively utilize pharmacological and psychotherapeutic techniques in their treatment of bipolar disorder. This volume outlines and demystifies current knowledge about neuropsychological functioning in bipolar disorder in a reader-friendly, easy-to-understand guide for practitioners. Its 12 chapters, written by 23 internationally-renowned expert contributors, examine such topics as attentional and executive functioning, neuroimaging and genetic correlates of cognitive functioning, pharmacological strategies, bipolar disorder in pediatric patients, and cognition across the life span. The book also comes with the added benefit of A review of neurocognitive domains, examples of their operation in everyday life, the neuroanatomical regions with which they are associated, and common tests used to assess their function Summarized data from large-scale clinical trials, including the National Institute of Mental Health Antipsychotic Trials of Intervention Effectiveness (CATIE) study Take-home points at the end of each chapter summarizing main concepts and "clinical pearls" Case studies and illustrative examples depicting the application of specific neurocognitive principles Using relevant applications from cognitive neuroscience, Cognitive Dysfunction in Bipolar Disorder provides clinicians with a comprehensive overview of astounding breakthroughs in the assessment and treatment of patients with bipolar disorder. It plows new ground in the mental health industry, correcting distortions and laying the foundation for future clinical research in this rapidly expanding field.

Mental Disorders and Disabilities Among Low Income Children

Mental Disorders and Disabilities Among Low Income Children
Author: National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Children, Youth, and Families,Board on the Health of Select Populations,Committee to Evaluate the Supplemental Security Income Disability Program for Children with Mental Disorders
Publsiher: National Academies Press
Total Pages: 472
Release: 2015-10-28
ISBN 10: 0309376882
ISBN 13: 9780309376884
Language: EN, FR, DE, ES & NL

Mental Disorders and Disabilities Among Low Income Children Book Review:

Children living in poverty are more likely to have mental health problems, and their conditions are more likely to be severe. Of the approximately 1.3 million children who were recipients of Supplemental Security Income (SSI) disability benefits in 2013, about 50% were disabled primarily due to a mental disorder. An increase in the number of children who are recipients of SSI benefits due to mental disorders has been observed through several decades of the program beginning in 1985 and continuing through 2010. Nevertheless, less than 1% of children in the United States are recipients of SSI disability benefits for a mental disorder. At the request of the Social Security Administration, Mental Disorders and Disability Among Low-Income Children compares national trends in the number of children with mental disorders with the trends in the number of children receiving benefits from the SSI program, and describes the possible factors that may contribute to any differences between the two groups. This report provides an overview of the current status of the diagnosis and treatment of mental disorders, and the levels of impairment in the U.S. population under age 18. The report focuses on 6 mental disorders, chosen due to their prevalence and the severity of disability attributed to those disorders within the SSI disability program: attention-deficit/hyperactivity disorder, oppositional defiant disorder/conduct disorder, autism spectrum disorder, intellectual disability, learning disabilities, and mood disorders. While this report is not a comprehensive discussion of these disorders, Mental Disorders and Disability Among Low-Income Children provides the best currently available information regarding demographics, diagnosis, treatment, and expectations for the disorder time course - both the natural course and under treatment.

Current and Emerging Issues in Cancer Pain

Current and Emerging Issues in Cancer Pain
Author: C. Richard Chapman,Kathleen M. Foley
Publsiher: Raven Press (ID)
Total Pages: 441
Release: 1993
ISBN 10:
ISBN 13: UOM:39015029888016
Language: EN, FR, DE, ES & NL

Current and Emerging Issues in Cancer Pain Book Review:

(Sympos. Seattle 7/92) Covers depression in the cancer patient emotional aspect of pain ethical issues etc.

Neuromodulation in Psychiatry

Neuromodulation in Psychiatry
Author: Clement Hamani
Publsiher: John Wiley & Sons
Total Pages: 496
Release: 2016-01-26
ISBN 10: 1118801040
ISBN 13: 9781118801048
Language: EN, FR, DE, ES & NL

Neuromodulation in Psychiatry Book Review:

"Neuromodulation strategies, including both invasive and non-invasive approaches, are growing in popularity. Transcranial magnetic stimulation has been approved for the treatment of depression, and an increasing number of patients have access to this intervention. At the other end of the spectrum, deep brain stimulation is showing promise for patients with severe, treatment-resistant psychiatric illness. Other neuromodulation approaches are in various stages of clinical use and/or investigation. Importantly, many of these approaches are no longer limited to tertiary centers, but can be office-based for greater accessibility. This book provides a comprehensive and detailed guide to the use of neuromodulation strategies in psychiatry. It begins with a review of the history of this controversial field and the lessons learned, followed by a chapter on the ethics of modern usage of such techniques. Subsequent chapters are devoted to neuromodulation and surgical strategies used in psychiatry, including transcranial magnetic stimulation, transcranial direct current stimulation, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation. For each technique, a chapter describes the basic principles of each technique, using figures and schematics to illustrate details for people who do not have personal experience of using these techniques. Another chapter then focuses on the results of clinical research, trials and applications for that strategy. The book is the first comprehensive reference work to cover all neuromodulation strategies now used or with potential use in psychiatry. It allows psychiatrists to evaluate results obtained using such strategies and to make decisions regarding the best course of treatment for their patients"--Provided by publisher.

Clinical Trials in Psychiatry

Clinical Trials in Psychiatry
Author: Brian S. Everitt,Simon Wessely
Publsiher: John Wiley & Sons
Total Pages: 248
Release: 2008-04-15
ISBN 10: 9780470723845
ISBN 13: 047072384X
Language: EN, FR, DE, ES & NL

Clinical Trials in Psychiatry Book Review:

At last – a new edition of the highly acclaimed book Clinical Trials in Psychiatry This book provides a concise but thorough overview of clinical trials in psychiatry, invaluable to those seeking solutions to numerous problems relating to design, methodology and analysis of such trials. Practical examples and applications are used to ground theory whenever possible. The Second Edition includes new information regarding: Recent important psychiatric trials More specific discussion of psychiatry in the USA and the particular problems of trials in the USA, including comments about the FDA (U.S. Food and Drug Administration) An extended chapter on meta-analysis Further discussion of sub-group analysis Special features include appendices outlining how to design and report clinical trials, what websites and software programs are appropriate and an extensive reference section. From the reviews of the First Edition: “Everitt & Wessely are to be congratulated on producing an excellent guide to help overcome the snags in clinical trial research. Clearly written and in an engrossing style, the book is likely to become a classic textbook on clinical trials, and not just in psychiatry. The authors’ enthusiasm and grasp of clinical trial research make for a gripping and insightful read...it is one of the very best books that has been written on clinical trials.” THE BRITISH JOURNAL OF PSYCHIATRY "The experience of both authors in this area gives the book a very pragmatic approach grounded in reality, with theoretical overviews invariably being followed by practical examples and applications... an invaluable companion to anyone involved in, or contemplating undertaking, clinical trials research.” PSYCHOLOGICAL MEDICINE

Clinical Staging in Psychiatry

Clinical Staging in Psychiatry
Author: Patrick D. McGorry,Ian B. Hickie
Publsiher: Cambridge University Press
Total Pages: 300
Release: 2019-07-31
ISBN 10: 1108718841
ISBN 13: 9781108718844
Language: EN, FR, DE, ES & NL

Clinical Staging in Psychiatry Book Review:

Clinical staging is a solution to transform psychiatric diagnosis and improve mental health outcomes.